BioSpace News Archive

Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), announced today that its wholly-owned clinical laboratory subsidiary, Applied DNA Clinical Labs (ADCL), has received conditional approval from the New York State Department of Health (NYSDOH) for its Linea™ 2.0 Assay (the “Linea 2.0 Assay”) as a Laboratory Developed Test (LDT), pending a final review of the assay’s validation data by NYSDOH.

Boundless Bio, a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA in aggressive cancers, announced that the Chief Executive Officer of Boundless Bio, Zachary Hornby, will present at the 40th Annual J.P. Morgan Healthcare Conference which will take place virtually.

Aytu BioPharma, Inc., a pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, announced that Mark Oki will join Aytu as the company’s chief financial officer effective January 17, 2022.

AbbVie (NYSE: ABBV) announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) to investigational telisotuzumab vedotin (Teliso-V) for the treatment of patients with advanced/metastatic epidermal growth factor receptor (EGFR) wild type, nonsquamous non-small cell lung cancer.

Tranquis Therapeutics announced its CEO, Sanjak Kakkar, M.D. will give a corporate presentation at the Biotech Showcase, being held January 10-19, 2022.

Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler, Chief Executive Officer, will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022 at 4:30 p.m. ET.

Artiva Biotherapeutics, Inc., an oncology company focused on developing and commercializing primary allogeneic natural killer (NK) cell therapies to treat cancer, today announced the appointment of Christopher Horan as Chief Technical Operations Officer.

G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the Company will participate in two upcoming virtual investor conferences in January.

Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and CEO, at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022 at 3:00 p.m. Eastern Standard Time.

POM Medical, LLC has expanded their Mercury Medical US Distribution Partnership with the signing of a European Distribution Agreement